pembrolizumab KEYTRUDA®

DRUG3 trials

Sponsors

Alpine Immune Sciences, Inc., Synthekine, IO Biotech

Conditions

1st Line NSCLCAdvanced Solid TumorLymphomaMelanomaNon Small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckUntreated Advanced NSCLC

Phase 1

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

TerminatedNCT04920383

Alpine Immune Sciences, Inc.Advanced Solid Tumor, Lymphoma

Start: 2021-06-22End: 2023-02-28Updated: 2024-03-01

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

RecruitingNCT05098132

Synthekine1st Line NSCLC, Advanced Solid Tumor, Non Small Cell Lung Cancer +1

Start: 2022-01-25End: 2029-01-01Target: 364Updated: 2026-07-10

Phase 2

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

RecruitingNCT05280314

IO BiotechMelanoma, Squamous Cell Carcinoma of Head and Neck

Start: 2023-12-21End: 2027-01-31Target: 60Updated: 2024-03-18

Related Papers

Abstract CT240: IOB-032/PN-E40: A phase 2 study of neoadjuvant/adjuvant IO102-IO103 cancer vaccine plus pembrolizumab in resectable HNSCC

Cancer Research2026-04-17

Abstract 6740: Selective immune activation of antigen activated T cells with STK-012, an a/b IL-2 receptor biased partial agonist, with pembrolizumab and chemotherapy in 1L PD-L1 negative non-squamous NSCLC

Cancer Research2026-04-03

Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Journal for ImmunoTherapy of Cancer2024-08-019 citations

Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab

Journal for ImmunoTherapy of Cancer2024-08-018 citations

A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.

Journal of Clinical Oncology2024-06-013 citations

Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)

Cancer Research2024-04-058 citations

738 Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2)

Regular and Young Investigator Award Abstracts2022-11-01

Abstract CT244: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132)

Cancer Research2022-06-151 citations

Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).

Journal of Clinical Oncology2022-06-012 citations

Davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies (NEON-2).

Journal of Clinical Oncology2022-06-011 citations

497 A Study of ALPN-202, a PD-L1-dependent CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in patients with advanced malignancies

Regular and Young Investigator Award Abstracts2021-11-01